Clinical Trials Browser

Phase 3 × Withdrawn × Gefitinib × Clear all

NCT03529084 2019-11-22

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00090675 2013-01-29

IMAC/Herbst

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung